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SCF-KIT Pathway in Human Epidermal Melanocyte
Homeostasis
To the Editor:
In the August issue of the Journal of Investigative Dermatology,
Grichnik et al (1998) demonstrated the responsiveness of adult
human melanocytes to stem cell factor (SCF) in vivo. We have
been interested in the role of SCF in postnatal skin since we
discovered the production of SCF by human keratinocytes, and
noted that the presence of the soluble form of SCF is associated
with locally increased pigment production in the epidermis of
patients with urticaria pigmentosa (Longley et al, 1993). These
observations first implicated local production of SCF in postnatal
melanocyte function. We agree with Grichnik et al (1998) that
their current findings are further evidence of the fundamental role
played by the SCF-KIT pathway in the regulation of melanocyte
proliferation and differentiation in human postnatal skin.
We would like to take this opportunity, however, to focus
discussion on the difference between the role of soluble SCF,
studied by Grichnik et al (1995) and others (Costa et al, 1996;
Grichnik et al, 1998), and the role of membrane-bound ker-
atinocyte-associated SCF. The majority of the immunoreactive
SCF found in normal human skin is bound to keratinocyte cell
membranes rather than being present in a soluble form, as originally
observed by us (Longley et al, 1993) and confirmed by others
(Hamann et al, 1995). Membrane-bound SCF and soluble SCF
have different effects on cells (Toksoz et al, 1992; Miyazawa et al,
1995), so the distinction may be important in vivo. In particular,
based on the following observations it appears that soluble SCF is
insufficient to support the normal migration and maintenance of
melanocytes in the skin.
Sl/Sld mice, whose cells produce only soluble SCF, are white
and have no melanocytes in the epidermis or hair follicles, indicating
that the soluble form of the molecule is incapable of supporting
melanocyte development and function (Silvers, 1979; Anderson
et al, 1990).
In normal mice, the gene for SCF is expressed in the epidermis
during development but not postnatally (Yoshida et al, 1996).
Consequently, the number of melanocytes (and melanoblasts)
present in the epidermis declines rapidly in the first few days
after birth, so that essentially no melanocytes are present in the
interfollicular epidermis of the adult mouse (Hirobe, 1984). The
color of the adult mouse therefore is a product of melanocytes that
are active in the hair follicles rather than the epidermis, which
lacks melanocytes and is unpigmented. This situation differs mark-
edly from human skin, in which epidermal keratinocytes express
SCF and melanocytes are maintained postnatally. We have recently
demonstrated the dominance of the membrane-associated form of
SCF using transgenic mice that express SCF in the basal layer of
the epidermis (Kunisada et al, 1998a). These studies show that the
membrane-bound form of SCF is required for melanocyte survival
in the epidermis, and that its expression in murine epidermis results
in the population of the epidermis by melanocytes. Thus, epidermal
membrane-bound SCF is both sufficient and necessary for normal
melanocyte function in the epidermis. Soluble SCF, it appears, is
associated with hyperfunction of melanocytes.
Also of relevance to the work of Grichnik et al (1996, 1998) are
studies using similar strains of the transgenic mice (Kunisada et al,
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1998b), which point to the presence of a cutaneous melanocyte
‘stem cell’ that, in mice, is not dependent on activation of KIT.
Whether these cells do not express the KIT receptor or are merely
not dependent on KIT activation for survival remains to be
determined experimentally; however, it would be interesting to
know whether the KIT-positive, TRP-1-negative cells described
by Grichnik et al (1996) are dependent on KIT for their survival.
One might expect to find melanocyte stem cells in the hair follicles
of normal mice, because there is no indication that melanocyte
stem cells are present in the interfollicular epidermis of nontrans-
genic mice.
B. Jack Longley and Eric L. Carter
Columbia University College of Physicians & Surgeons, New
York, New York, USA
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Reply
Given the current understanding of SCF expression patterns, we
believe, as Drs Longly and Carter suggest, that the keratinocyte
bound form of SCF will be the primary player in the control of
normal human melanocyte homeostasis in the epidermis.
As Drs Longley and Carter point out, SCF has two known splice
forms. Both SCF forms are initially expressed as membrane bound
proteins but one can be cleaved into a ‘‘soluble’’ form whereas the
other remains bound on the cell surface due to the absence of an
exon. The region involved in KIT activation is the same for both
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molecules. Our experiments focused on the injection of the soluble
form of SCF and inhibition of the KIT pathway with monoclonal
antibody K44.2 (Grichnik et al 1998). Because both forms of SCF
stimulate the KIT receptor, we believe the results of our experiments
are applicable for both the soluble and the membrane bound forms
of SCF. K44.2 inhibits the binding of soluble SCF to KIT (Blechman
et al, 1995) but we have no reason to suspect that it does not also
inhibit the binding of membrane bound SCF. Our findings support
the importance of the SCF/KIT interaction to human melanocytes
and do not exclude bound SCF.
While both forms of SCF activate KIT, we suspect that the
duration of activation and potential for receptor degradation is
different for each form. Keratinocytic bound SCF may lock on to
the melanocyte’s KIT receptor resulting in persistent KIT activation
(without KIT receptor internalization and degradation), while
soluble SCF may transiently activate the KIT receptor followed by
internalization and degradation.
The role of KIT on the variety of melanocytic differentiation
states remains for the most part unknown. It is possible that KIT
expression on melanocytes is regulated through at least two
mechanisms, one central (transcriptional) and one peripheral
(feedback through receptor). If the central expression is low the
melanocytic cells may function independently from the KIT
pathway. If central expression is high, then cells become susceptible
to KIT activation or inhibition. Peripheral KIT activation may also
result in apparent KIT downregulation through negative feedback.
Following this logic the KIT 1 TRP-1(–) cells (normal skin,
Grichnik et al, 1996; nevus depigmentous, Dippel et al, 1995)
IgG1 and IgG3 are the Major Immunoglobulin Subclasses
Targeting Epitopes within the NC16A Domain of BP180 in
Pemphigoid Gestationis
To the Editor:
Pemphigoid gestationis (PG) is a subepidermal blistering disease
characterized by the linear depositon of C3 and, to a lesser extent,
IgG at the cutaneous basement membrane zone (BMZ) as detected
by direct immunofluorescence (IF) (Shornick, 1987). Indirect IF
studies demonstrated that circulating autoantibodies of PG sera are
predominantly of the IgG1 subclass (Kelly et al, 1989). The
autoimmune response in PG is directed against two hemidesmo-
somal proteins, BP180 and, less frequently, BP230 (Morrison et al,
1988). The pathogenic relevance of autoantibodies against BP180
in PG and bullous pemphigoid (BP) was established using a passive
transfer animal model (Liu et al, 1993). BP180 is a transmembrane
glycoprotein with a large extracellular C-terminal ectodomain
containing 15 interrupted collageneous domains (Giudice et al,
1992; Hopkinson et al, 1992; Li et al, 1993). Immunoelectron
microscopy studies have shown that the BP180 ectodomain tran-
verses the lamina lucida and projects into the lamina densa (Bedane
et al, 1997; Masunaga et al, 1997). It might interact with one or
more proteins of the epidermal BMZ thus promoting the adhesion
of basal keratinocytes. Recently, it was demonstrated that anti-
BP180 antibodies in BP recognize four major epitopes on its
membrane-proximal NC16A domain (Zillikens et al, 1997a), and
that one of these antigenic sites (designated NC16A2 or MCW-1)
is also recognized by PG sera (Giudice et al, 1993). The purpose
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should be particularly susceptible to KIT inhibition; however, we
have no specific data to support or refute this hypothesis.
There are still quite a number of challenges ahead. How is SCF
normally regulated on human keratinocytes? How is the KIT
receptor regulated on the melanocyte? Is there a functional autocrine
pathway for SCF/KIT in melanocytic disease states? What are the
different differentiation states of melanocytes? Which differentiation
states are dependent or independent of SCF? Can these states be
reversed in normal melanocytes, or in melanoma?
The myriad of different pigmentation states, nevi, and melanoma
types suggests that we have a relatively complex biologic puzzle to
work out. We believe the SCF/KIT pathway will factor into many
of these processes at some capacity. We look forward to the next
millennium and to the answers for many of these questions.
James M. Grichnik
Duke University Medical Center, Division of Dermatology,
Durham, North Carolina, USA
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of this study was to characterize the epitopes within BP180 NC16A
targeted by PG autoantibodies and to determine their subclass
distribution.
Sera were obtained from 21 PG patients before treatment was
initiated. All patients showed deposits of C3 and/or IgG at the
BMZ by direct and/or indirect IF and demonstrated autoantibodies
against BP180 NC16A by both ELISA and immunoblot analysis
(Zillikens et al, 1997b). Twelve well-characterized BP sera and 10
normal human sera (NHS) were used as controls. Rabbit serum
R58 was raised against recombinant glutathione S-transferase (GST).
Reactivity of PG sera with different segments of BP180 NC16A
was assayed by immunoblotting using the following recombinant
GST fusion proteins: GST-NC16A1, GST-NC16A2, GST-
NC16A2.5, GST-NC16A3, GST-NC16A1–3, GST-NC16A2–4,
GST-NC16A2–5, and GST-NC16A1–5. Preparation of these pro-
teins, and immunoblotting and immunoadsorption procedures were
performed as described (Giudice et al, 1993; Zillikens et al, 1997a).
The secondary peroxidase-conjugated antibodies were used at the
following dilutions: goat antirabbit polyclonal IgG 1:5000; rabbit
antihuman polyclonal IgG 1:15 000; antihuman IgM 1:5000 (all
DAKO, Glostrup, Denmark); antihuman IgA 1:20 000 (Jackson
Immunoresearch Laboratories, West Grove, PA); sheep antihuman
IgE 1:100; mouse antihuman IgG1 (clone 8c/6–39) 1:1000; anti-
human IgG2 (clone HP6014) 1:500; antihuman IgG3 (clone
HP6050) 1:200; antihuman IgG4 (clone HP6023) 1:4000 (all
Binding Site, Birmingham, UK). Monoclonal antibodies were
demonstrated to be specific by direct hemagglutination and hemag-
glutination inhibition assays (Jefferis et al, 1985), and by immunoblot
analysis using human IgG1, IgG2, IgG3, IgG4 myeloma proteins
(Sigma, St. Louis, MO). Sensitivities of secondary monoclonal
